The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CUE | -58% | -94.71% | -44.41% | -95% |
| S&P | +13.19% | +87.83% | +13.42% | +150% |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.
The streaming video veteran has created a lot of shareholder wealth in recent years. These stocks just might do even better in the future.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.15M | -35.6% |
| Gross Profit | $2.07M | -15.8% |
| Gross Margin | 96.32% | 22.7% |
| Market Cap | $55.23M | 49.9% |
| Market Cap / Employee | $1.35M | 0.0% |
| Employees | 41 | -22.6% |
| Net Income | -$7.45M | 14.0% |
| EBITDA | -$7.47M | 7.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.70M | -63.9% |
| Accounts Receivable | $0.39M | -87.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.68M | 1.1% |
| Short Term Debt | $3.49M | -49.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -98.58% | -20.1% |
| Return On Invested Capital | -103.62% | -30.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.02M | -19.9% |
| Operating Free Cash Flow | -$9.02M | -19.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.59 | 3.22 | 6.41 | 3.03 | 77.61% |
| Price to Sales | 8.71 | 8.47 | 7.86 | 10.21 | 150.90% |
| Price to Tangible Book Value | 2.59 | 3.22 | 6.41 | 3.03 | 77.61% |
| Enterprise Value to EBITDA | -6.82 | -5.40 | -5.30 | -8.04 | 306.47% |
| Return on Equity | -149.0% | -221.7% | -195.5% | -195.2% | 48.83% |
| Total Debt | $8.88M | $7.13M | $7.63M | $6.17M | -35.10% |
No podcast episodes available.
CUE earnings call for the period ending March 31, 2020.
CUE earnings call for the period ending March 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
